In this Review, we describe the pathogenesis, diagnosis and management of primary hyperparathyroidism (PHPT), with a focus on recent advances in the field. PHPT is a …
AE Mirrakhimov - North American journal of medical sciences, 2015 - ncbi.nlm.nih.gov
Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an updated review on the etiology, pathogenesis …
JP Bilezikian, LG Raisz, TJ Martin - 2008 - books.google.com
Principles of Bone Biology provides the most comprehensive, authoritative reference on the study of bone biology and related diseases. It is the essential resource for anyone involved …
E Shane - The Journal of Clinical Endocrinology & Metabolism, 2001 - academic.oup.com
Parathyroid carcinoma is an uncommon cause of PTH-dependent hypercalcemia. The collective published experience with this rare neoplasm has provided a distinctive clinical …
D Riccardi, EM Brown - American Journal of Physiology …, 2010 - journals.physiology.org
The extracellular calcium-sensing receptor (CaSR) plays a major role in the maintenance of a physiological serum ionized calcium (Ca2+) concentration by regulating the circulating …
NL Busaidy, C Jimenez, MA Habra… - Head & Neck …, 2004 - Wiley Online Library
Purpose. Because parathyroid carcinoma is rare, clear consensus is not available regarding the optimal management of patients with this condition. Treatment strategies generally …
J Tfelt-Hansen, EM Brown - Critical reviews in clinical laboratory …, 2005 - Taylor & Francis
The discovery of a G protein–coupled, calcium-sensing receptor (CaR) a decade ago and of diseases caused by CaR mutations provided unquestionable evidence of the CaR's critical …
SJ Silverberg, MR Rubin, C Faiman… - The Journal of …, 2007 - academic.oup.com
Background: Management of inoperable parathyroid carcinoma presents a challenge because until recently, effective medical therapy was not available. Morbidity and mortality …
C Marcocci, F Cetani, MR Rubin… - Journal of Bone and …, 2008 - academic.oup.com
Dr Marcocci claims a consultancy and lists himself as a member of the international advisory board for Amgen. Dr Bilezikian has served as a consultant to Merck, Lilly, Amgen, NpS …